1-7 of 7
Jamie E. Chaft
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

Rohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, Daniel Muldoon, Hira Rizvi, Arielle Elkrief, Jia Luo, Joao V. Alessi, Federica Pecci, Giuseppe Lamberti, Alessandro Di Federico, Lingzhi Hong, Jianjun Zhang, John V. Heymach, Don L. Gibbons, Andrew J. Plodkowski, Vignesh Ravichandran, Mark T.A. Donoghue, Chad Vanderbilt, Marc Ladanyi, Charles M. Rudin, Mark G. Kris, Gregory J. Riely, Jamie E. Chaft, Matthew D. Hellmann, Natalie I. Vokes, Mark M. Awad, Adam J. Schoenfeld
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4408–4418.
https://doi.org/10.1158/1078-0432.CCR-23-1207
Published: 01 November 2023
View article titled, Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer

Samuel Rosner, Joshua E. Reuss, Marianna Zahurak, Jiajia Zhang, Zhen Zeng, Janis Taube, Valsamo Anagnostou, Kellie N. Smith, Joanne Riemer, Peter B. Illei, Stephen R. Broderick, David R. Jones, Suzanne L. Topalian, Drew M. Pardoll, Julie R. Brahmer, Jamie E. Chaft, Patrick M. Forde
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (4): 705–710.
https://doi.org/10.1158/1078-0432.CCR-22-2994
Published: 16 February 2023
View article titled, Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
Open the PDF for Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC

Matthew D. Hellmann, Barzin Y. Nabet, Hira Rizvi, Aadel A. Chaudhuri, Daniel K. Wells, Mark P.S. Dunphy, Jacob J. Chabon, Chih Long Liu, Angela B. Hui, Kathryn C. Arbour, Jia Luo, Isabel R. Preeshagul, Everett J. Moding, Diego Almanza, Rene F. Bonilla, Jennifer L. Sauter, Hyejin Choi, Megan Tenet, Mohsen Abu-Akeel, Andrew J. Plodkowski, Rocio Perez Johnston, Christopher H. Yoo, Ryan B. Ko, Henning Stehr, Linda Gojenola, Heather A. Wakelee, Sukhmani K. Padda, Joel W. Neal, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Taha Merghoub, Bob T. Li, Ash A. Alizadeh, Maximilian Diehn
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12): 2849–2858.
https://doi.org/10.1158/1078-0432.CCR-19-3418
Published: 15 June 2020
View article titled, Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
Open the PDF for Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC in another window
Includes: Supplementary data
Journal Articles

Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer

Jiajia Zhang, Zhicheng Ji, Justina X. Caushi, Margueritta El Asmar, Valsamo Anagnostou, Tricia R. Cottrell, Hok Yee Chan, Prerna Suri, Haidan Guo, Taha Merghoub, Jamie E. Chaft, Joshua E. Reuss, Ada J. Tam, Richard L. Blosser, Mohsen Abu-Akeel, John-William Sidhom, Ni Zhao, Jinny S. Ha, David R. Jones, Kristen A. Marrone, Jarushka Naidoo, Edward Gabrielson, Janis M. Taube, Victor E. Velculescu, Julie R. Brahmer, Franck Housseau, Matthew D. Hellmann, Patrick M. Forde, Drew M. Pardoll, Hongkai Ji, Kellie N. Smith
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (6): 1327–1337.
https://doi.org/10.1158/1078-0432.CCR-19-2931
Published: 13 March 2020
View article titled, Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer
Open the PDF for Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas

Maria E. Arcila, Jamie E. Chaft, Khedoudja Nafa, Sinchita Roy-Chowdhuri, Christopher Lau, Michael Zaidinski, Paul K. Paik, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (18): 4910–4918.
https://doi.org/10.1158/1078-0432.CCR-12-0912
Published: 16 September 2012
View article titled, Prevalence, Clinicopathologic Associations, and Molecular Spectrum of <em>ERBB2</em> (<em>HER2</em>) Tyrosine Kinase Mutations in Lung Adenocarcinomas
Open the PDF for Prevalence, Clinicopathologic Associations, and Molecular Spectrum of <em>ERBB2</em> (<em>HER2</em>) Tyrosine Kinase Mutations in Lung Adenocarcinomas in another window
Includes: Supplementary data
Journal Articles

Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

Jamie E. Chaft, Geoffrey R. Oxnard, Camelia S. Sima, Mark G. Kris, Vincent A. Miller, Gregory J. Riely
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (19): 6298–6303.
https://doi.org/10.1158/1078-0432.CCR-11-1468
Published: 02 October 2011
View article titled, Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with <em>EGFR</em>-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design
Open the PDF for Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with <em>EGFR</em>-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design in another window
Journal Articles

Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene

Naiyer A. Rizvi, Valerie Rusch, William Pao, Jamie E. Chaft, Marc Ladanyi, Vincent A. Miller, Lee M. Krug, Christopher G. Azzoli, Manjit Bains, Robert Downey, Raja Flores, Bernard Park, Bhuvanesh Singh, Maureen Zakowski, Robert T. Heelan, Ronglai Shen, Mark G. Kris
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3500–3506.
https://doi.org/10.1158/1078-0432.CCR-10-2102
Published: 15 May 2011
View article titled, Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the <em>EGFR</em> Gene
Open the PDF for Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the <em>EGFR</em> Gene in another window